ArticlePharmaceutics2022
Pharmacokinetics and Anti-Diabetic Studies of Gliclazide Nanosuspension.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Nilotinib-loaded hydroxy propyl β-cyclodextrin nanosponges for improved oral bioavailability in chronic myeloid leukemia therapy.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Green Approach to Enhance Dissolution of Gliclazide: Thermoresponsive Solid Dispersion Based on Poloxamer 188/Propylene Glycol/Labrasol Ternary System.Pharmaceutics · 2026Article
- The Role and Potential of Nanotechnology in Improving Solubility and Enhancing Bioavailability.Pharmaceutics · 2026Review
- Hydroxypropyl Methylcellulose-A Key Excipient in Pharmaceutical Drug Delivery Systems.Pharmaceutics · 2025Review
- Optimizing ibrutinib bioavailability: Formulation and assessment of hydroxypropyl-β-cyclodextrin-based nanosponge delivery systems.Current research in pharmacology and drug discovery · 2025Article
- Nano-Based Drug Delivery Systems for Managing Diabetes: Recent Advances and Future Prospects.International journal of nanomedicine · 2025Review
- Drug Nanocrystals in Oral Absorption: Factors That Influence Pharmacokinetics.Pharmaceutics · 2024Review
- Highly Drug-Loaded Nanoaggregate Microparticles for Pulmonary Delivery of Cyclosporin A.International journal of nanomedicine · 2024Article
- Biological Activities ofMolecules (Basel, Switzerland) · 2023Article
- Formulation Strategies of Nanosuspensions for Various Administration Routes.Pharmaceutics · 2023Review
- Development of Biocompatible Ciprofloxacin-Gold Nanoparticle Coated Sutures for Surgical Site Infections.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliclazide (GCZ), an antidiabetic medication, has poor solubility and limited oral bioavailability due to substantial first-pass metabolism. Thus, the purpose of the current study was to optimize and formulate a GCZ nanosuspension (NS) employing the antisolvent precipitation technique. A three-factor, three-level Box-Behnken design (BBD) was used to examine the impact of the primary formulation factors (drug concentration, stabilizer, and surfactant %) on particle size. The optimized NS contains 29.6 mg/mL drug, 0.739% lecithin, and 0.216% sodium dodecyl sulfate (SDS). Under scanning microscopy, the topography of NS revealed spherical particles. Furthermore, NS had a much better saturation solubility than the pure material, which resulted in a rapid dissolving rate, which was attributed to the amorphous structure and smaller particle size of the NS particles. Studies on intestinal permeability using the in vitro noneverted intestinal sac gut method (duodenum, jejunum, and ileum) and single-pass intestinal permeability (SPIP) techniques showed that the effective permeability was also increased by more than 3 fold. In the pharmacokinetic study, the C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.